StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy
June 22, 2015 7:03 AM EDTCantor Fitzgerald reiterates a Buy rating and $2.00 price target on StemCells (NASDAQ: STEM) ahead of GA data that is anticipated to be Presented this week. Analyst Caroline Corner expects positive results, based on interim data.
Corner commented, "We anticipate that data will be... More
StemCells (STEM) Receives Approval from Health Canada to Expand Pathway Study
June 18, 2015 8:06 AM EDTStemCells (NASDAQ: STEM) announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human... More
